NCT03872427: A trial that was reported late by National Cancer Institute (NCI)
This trial has reported, although it was 230 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03872427 |
|---|---|
| Title | A Phase II Basket Trial of Glutaminase Inhibitor (BEGIN) Telaglenastat (CB-839) HCL in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 14, 2019 |
| Completion date | Oct. 30, 2023 |
| Required reporting date | Oct. 29, 2024, midnight |
| Actual reporting date | June 17, 2025 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 230 |